达格列净在心力衰竭全射血分数谱中的性别差异:DAPA-HF与DELIVER汇总分析
结果显示达格列净在男女患者中降低主要终点事件的效果相似(Pinteraction=0.77),且在全射血分数谱中获益不受性别影响(Pinteraction>0.40),安全事件无性别差异。
要点
- 达格列净在男女心衰患者中疗效相似,主要终点交互作用P=0.77。
- 女性心衰患者基线特征与男性不同,但调整后心血管死亡和心衰住院风险更低。
- 达格列净在全射血分数谱中的获益不受性别影响,安全事件无性别差异。
核心结论
- 在DAPA-HF和DELIVER汇总分析中,达格列净的治疗反应在男女之间相似,性别未改变达格列净在全射血分数范围内的疗效。
主要发现
- 女性心衰患者较男性年龄更大、体重指数更高,糖尿病、心肌梗死或卒中病史更少,高血压和房颤更多。
- 基线时女性射血分数高于男性,但堪萨斯城心肌病问卷评分更差。
- 调整基线差异后,女性较男性心血管死亡风险更低(调整后风险比0.69,95%CI 0.60-0.79)。
- 调整后女性全因死亡风险更低(调整后风险比0.69,95%CI 0.62-0.78),心衰住院风险更低(调整后风险比0.82,95%CI 0.72-0.94),总事件风险更低(调整后率比0.77,95%CI 0.71-0.84)。
- 达格列净在男女中降低主要终点的效果相似(Pinteraction=0.77),次要结局无性别相关差异(所有Pinteraction>0.35),安全事件无性别差异,全射血分数谱获益不受性别影响(Pinteraction>0.40)。
临床怎么用
- 达格列净可用于男性和女性心衰患者,全射血分数谱获益一致,无需因性别调整治疗预期。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sodium-glucose cotransporter-2 inhibitors have emerged as a key pharmacotherapy in heart failure (HF) with both reduced and preserved ejection fraction. The benefit of other HF therapies may be modified by sex, but whether sex modifies the treatment effect and safety profile of sodium-glucose cotransporter-2 inhibitors remains unclear. Our analyses aim to assess the effect of sex on the efficacy and safety of dapagliflozin. METHODS: In a prespecified patient-level pooled analysis of DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure) and DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure), clinical outcomes were compared by sex (including the composite of cardiovascular death or worsening HF events, cardiovascular death, all-cause death, total events [first and recurrent HF hospitalization and cardiovascular death], and Kansas City Cardiomyopathy Questionnaire scores) across the spectrum of left ventricular ejection fraction. RESULTS: Of a total of 11 007 randomized patients, 3856 (35%) were women. Women with HF were older and had higher body mass index but were less likely to have a history of diabetes and myocardial infarction or stroke and more likely to have hypertension and atrial fibrillation compared with men. At baseline, women had higher ejection fraction but worse Kansas City Cardiomyopathy Questionnaire scores than men did. After adjustment for baseline differences, women were less likely than men to experience cardiovascular death (adjusted hazard ratio, 0.69 [95% CI, 0.60-0.79]), all-cause death (adjusted hazard ratio, 0.69 [95% CI, 0.62-0.78]), HF hospitalizations (adjusted hazard ratio, 0.82 [95% CI, 0.72-0.94]), and total events (adjusted rate ratio, 0.77 [95% CI, 0.71-0.84]). Dapagliflozin reduced the primary end point in both men and women similarly (Pinteraction=0.77) with no sex-related differences in secondary outcomes (all Pinteraction>0.35) or safety events. The benefit of dapagliflozin was observed across the entire ejection fraction spectrum and was not modified by sex (Pinteraction>0.40). There were no sex-related differences in serious adverse events, adverse events, or drug discontinuation attributable to adverse events. CONCLUSIONS: In DAPA-HF and DELIVER, the response to dapagliflozin was similar between men and women. Sex did not modify the treatment effect of dapagliflozin across the range of ejection fraction.
引用
- Wang, Vaduganathan, Claggett, et al. Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER. Circulation. 2022. PMID: 36342789. doi:10.1161/CIRCULATIONAHA.122.062832
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。